Zentalis Pharmaceuticals, Inc.
13.4M
$315.15M
-0.71
$-1.91
No price alerts set. Add an alert to get notified!
-0.71
0.45
$-1.91
-63.39%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ALXO
ALX Oncology Holdings Inc.
|
$1.70 | -10.29% | -0.91 | $92.19M | 0.20 |
|
ARTV
Artiva Biotherapeutics, Inc.
|
$6.80 | 9.85% | -1.98 | $168.07M | 0.10 |
|
DTIL
Precision BioSciences, Inc.
|
$6.61 | 10.35% | -1.82 | $84.79M | 0.31 |
|
IMMX
Immix Biopharma, Inc.
|
$9.87 | 12.80% | -12.84 | $522.75M | 0.01 |
|
MGNX
MacroGenics, Inc.
|
$3.44 | -0.29% | -2.91 | $218.63M | 1.92 |
|
PLRX
Pliant Therapeutics, Inc.
|
$1.35 | -0.74% | -0.55 | $83.58M | 0.16 |
|
STRO
Sutro Biopharma, Inc.
|
$26.76 | -1.07% | -1.20 | $227.40M | -1.78 |
|
STTK
Shattuck Labs, Inc.
|
$7.40 | 5.41% | -15.73 | $354.48M | 0.02 |
|
TIL
Instil Bio, Inc.
|
$8.48 | -0.76% | -0.81 | $57.48M | 0.75 |
|
WHWK
Whitehawk Therapeutics Inc
|
$3.55 | 4.11% | -11.93 | $167.55M | 0.00 |
* Peer stocks are selected based on market capitalization and sector
$4.50
$1.01
$0.00
0.00%
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
